Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Introduction
00:00 • 2min
Roy Van: A Company That's Different From Other Companies
01:47 • 2min
The Pros and Cons of Tl1 A
04:12 • 3min
Vivek Rammaswami and the Fda
07:31 • 2min
Riven's Disagreement With Roiven
09:17 • 3min
The Evolution of Ionized to Vent 1.0
12:00 • 2min
The Importance of Partnership With Big Pharma Companies
13:40 • 3min
Biogen Announced Earnings on Wednesday
16:37 • 5min
Riada: A Unique Asset in the Neurology Sector
21:44 • 2min
The Bioplausibility of Reata's Oxalone
23:47 • 4min
Biogen's Layoffs and Executive Changes
28:08 • 4min
The Turbulence in the Biotech Industry
32:25 • 4min
Al Nilum and Roche Get Together on R&A Asset
36:33 • 2min
The Challenges of Big Pharma's Dance With the Technologies of the Future
38:31 • 4min
Gilead and the HIV Platform
42:04 • 2min
The Allegations Against Gilead on TAF
44:26 • 2min
Gilead's Slow Walk Development of TAF
46:40 • 2min
Gilead's CD47 Acquisition of McGrollumab
48:21 • 4min
The Insider Trading Scandal
51:57 • 2min
Stoke Therapeutics and Kodiak Sciences Hit a Bump in the Road With Drug Development
54:00 • 3min
What Company Do We Not Know About Head Really Bad?
56:48 • 1min
The Future of Lupus Research
58:17 • 2min